{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001737953","name":"Replimune Group, Inc.","summary":"Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment. Its proprietary RPx platform is based on an engineered HSV-1 backbone designed to maximize immunogenic cell death and systemic anti-tumor immune response. Lead product RP1 (vusolimogene oderparepvec) is being evaluated in melanoma and non-melanoma skin cancers, with a BLA submitted to the FDA in combination with nivolumab for anti-PD-1 failed advanced melanoma, granted priority review with a PDUFA date of July 22, 2025.","people":[],"products":[{"name":"RP1 (vusolimogene oderparepvec)","type":"platform","description":"Lead oncolytic immunotherapy candidate based on engineered HSV-1; being evaluated in melanoma and non-melanoma skin cancers, including in combination with nivolumab; BLA submitted under accelerated approval pathway."},{"name":"RP2","type":"platform","description":"Second RPx platform-based oncolytic immunotherapy candidate currently in clinical development pipeline."},{"name":"RP3","type":"platform","description":"Third RPx platform-based oncolytic immunotherapy candidate currently in clinical development pipeline."},{"name":"RPx Platform","type":"platform","description":"Proprietary engineered HSV-1 backbone platform designed for oncolytic immunotherapy with dual local and systemic anti-tumor activity."}],"partnerships":[{"partner_name":"Bristol Myers Squibb Company (BMS)","partnership_type":"development","description":"BMS granted non-exclusive royalty-free license and supplies nivolumab at no cost for use in combination with RP1 in the IGNYTE clinical trial.","start_date":null}],"affiliations":[],"origin":{"leaf":"ba0692ccabed2c09386a4e9c17b16c27c8cab6e84cfba34862412896f42c5a5b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a5b98fb053cc60681919f803b40698f188cccead6f14481ce537707ffac766ae","parent":"8ece05071b73c6b98fab400bc77847269bbfd924483fb54ebe7b2d3133c757e1","source":"0001737953-25-000009","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}